A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Clinical Trial ID NCT02019693

PubWeight™ 3.18‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02019693

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer statistics, 2012. CA Cancer J Clin 2012 87.38
2 Renal-cell carcinoma. N Engl J Med 2005 10.17
3 Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol 2012 1.00
4 c-Met as a Target for Personalized Therapy. Transl Oncogenomics 2015 0.92
5 Has MET met its match? Ann Transl Med 2016 0.76
6 Genetic predisposition to kidney cancer. Semin Oncol 2016 0.75
7 Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis. Ann Transl Med 2016 0.75
Next 100